what if nicknamed WHAT-IF? for the question, “will having alcohol treatment improve functioning?”

The Pharmacotherapy for hazardous drinking in HIV-infected women: a randomized trial, aims to enroll 240 women with HIV infection who exceed recommended drinking levels (>7 drinks per week). The study will determine whether a specific drug, naltrexone, will help reduce drinking levels in HIV-infected women, thus improving their HIV-related outcomes such as adherence to medication, CD4 count and viral load. Women are randomized to take naltrexone (50mg) or placebo every day for 4 months. Outcomes, assessed at 2-months, 4-months, and 7-months, include alcohol consumption, HIV medication adherence, HIV disease control and progression, and risky sexual behavior. Enrollment began in December of 2012, and has now concluded. The data is still available for anyone interested in submitting a concept.

What If Measures

Baseline/Follow-up Questionnaires

  • Demographics
  • Brief Pain Inventory
  • Medication Adherence
  • SF-12 for Health Condition
  • Short Inventory of Problem (SIP)
  • Domestic Violence
  • Belief/Attitude about treatment of hazardous drinking
  • Addiction Severity
  • Sexual Risk Measures
  • HIV Women Health Services Utilization

MINI Partial Interview: alcohol dependence/abuse

Timeline Follow Back Interview: self-reported drinking patterns

Concomitant Medications

Visit Forms:

  • Concomitant Medications
  • Visit Forms:Laboratory tests
  • Pre-existing conditions
  • CRC assessment
  • BSI and physical activity
  • AUDIT 10
  • Side effects and other adverse events
  • Pill count
  • Brief import persons

Current and Completed Florida Cohort Concepts